Pharmacogenomics-guided policy in opioid use disorder (OUD) management: An ethnically-diverse case-based approach

Amass, 2012, A prospective, randomized, multicenter acceptability and safety study of direct buprenorphine/naloxone induction in heroin-dependent individuals, Addiction, 107, 142, 10.1111/j.1360-0443.2011.03577.x APA FDA, 2013, 1 Gunderson, 2015, Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: A multicenter, randomized trial, Clinical Therapeutics, 37, 2244, 10.1016/j.clinthera.2015.08.025 Indivior, 2015 Issa, 2013 Merriam-Webster Dictionary Merriam-Webster Dictionary Merriam-Webster Dictionary NIDA NIH NIH Picard, 2005, In vitro metabolism study of buprenorphine: Evidence for new metabolic pathways, Drug Metabolism and Disposition, 33, 689, 10.1124/dmd.105.003681 Rendic, 1997, Human cytochrome P450 enzymes: A status report summarizing their reactions, substrates, inducers, and inhibitors, Drug Metabolism Reviews, 29, 413, 10.3109/03602539709037591 Rouguieg, 2010, Contribution of the different UDP-glucuronosyltransferase (UGT) isoforms to buprenorphine and norbuprenorphine metabolism and relationship with the main UGT polymorphisms in a bank of human liver microsomes, Drug Metabolism and Disposition, 38, 40, 10.1124/dmd.109.029546 SAMHSA SAMHSA Schuckit Somogyi, 2015, Pharmacogenetics of opioid response, Clinical Pharmacology and Therapeutics, 97, 125, 10.1002/cpt.23 Westlind-Johnsson, 2006, Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity, Clinical Pharmacology and Therapeutics, 79, 339, 10.1016/j.clpt.2005.11.015 Whirl-Carrillo, 2012, Pharmacogenomics knowledge for personalized medicine, Clinical Pharmacology and Therapeutics, 92, 414, 10.1038/clpt.2012.96 WHO, 2011